Innovent Biologics, Inc.
IVBXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $52 | $54 | $44 | $57 |
| - Cash | $8 | $10 | $1 | $1 |
| + Debt | $3 | $4 | $3 | $2 |
| Enterprise Value | $47 | $48 | $46 | $58 |
| Revenue | $9 | $6 | $5 | $4 |
| % Growth | 51.8% | 36.2% | 6.7% | – |
| Gross Profit | $8 | $4 | $4 | $4 |
| % Margin | 84% | 70.9% | 79.6% | 86.6% |
| EBITDA | -$0 | -$1 | -$2 | -$2 |
| % Margin | -5.1% | -10.6% | -38.4% | -55.6% |
| Net Income | -$0 | -$1 | -$2 | -$3 |
| % Margin | -1% | -16.6% | -47.8% | -63.9% |
| EPS Diluted | -0.056 | -0.66 | -1.46 | -1.88 |
| % Growth | 91.5% | 54.8% | 22.3% | – |
| Operating Cash Flow | $1 | $0 | -$2 | -$2 |
| Capital Expenditures | -$2 | -$1 | -$1 | -$2 |
| Free Cash Flow | -$0 | -$1 | -$3 | -$4 |